Cargando…
Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials
INTRODUCTION: Sodium glucose cotransporter 2 (SGLT2) inhibitors have a unique mecha-nism of action leading to excretion of glucose in the urine and subsequent lowering of plasma glu-cose. This mechanism is independent of β-cell function; thus, these agents are effective treatment for type 2 diabetes...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Science Publishers
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5543566/ https://www.ncbi.nlm.nih.gov/pubmed/27296042 http://dx.doi.org/10.2174/1573399812666160613113556 |